Project Grant HT94252510050
Award Date
6/1/25
Completion Date
5/31/29
Dollars Obligated
$4.9M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Pittsburgh, PA 15260, USA
Similar Awards
This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program provides $346,319 to the University of Pittsburgh to conduct research on intragenic rearrangement burden as a genomic predictor of immunotherapy benefit in triple-negative breast cancer. The award period runs from August 1, 2024 to July 31, 2027. The University of Pittsburgh, a major public research university, will leverage its extensive scientific...
The University of Pittsburgh was awarded a $1,541,823 Project Grant by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant is for the project "FAST TILS TO TREAT METASTATIC CANCER PATIENTS WITH PLEURAL DISEASE" and runs from November 1, 2024 to October 31, 2028. The grant supports advanced biomedical research initiatives focused on transforming healthcare for military service members and the broader public, with a...
The University of Pittsburgh was awarded a $925,680 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from August 1, 2023 to July 31, 2027 targeting the IGFBP2-SRC signaling axis to block metastatic spread and tumor-mesothelial crosstalk. Through this research, the University aims to develop medical solutions for the battlefield by investigating approaches to prevent cancer metastasis. The Military...
The University of Pittsburgh was awarded a $954,000 Project Grant from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will support research from May 2023 to May 2026 aimed at epigenetic reprogramming to target senescent ovarian cancer cells and overcome therapeutic resistance. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform military and public...
The University of Pittsburgh received a $454,142.00 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct research on "FERROPTOSIS AS A METABOLIC VULNERABILITY OF CYCLIN E-HIGH OVARIAN CANCER". This 2-year research project, with a performance period from May 2024 to May 2026, aims to investigate metabolic vulnerabilities in a specific type of ovarian cancer. The University of Pittsburgh is the primary...
This $1,264,474 federal Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports the University of Pittsburgh's research on "Molecular Insights into Immune Suppression in Kidney Cancer and Novel Therapeutic Opportunities". The grant, effective September 1, 2024 through August 31, 2028, will fund the university's investigations into improving understanding of immune system mechanisms involved in kidney cancer and...
This $846,182 Project Grant award to the University of Pittsburgh was made by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant will fund a research project titled "INTRAGENIC REARRANGEMENT BURDEN AS A GENOMIC PREDICTOR OF IMMUNOTHERAPY BENEFIT IN TRIPLE-NEGATIVE BREAST CANCER" with a performance period from Aug 1, 2024 to Jul 31, 2027. As a major research university, the University of Pittsburgh will leverage its extensive...
This $1,430,088 Project Grant award from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) supports research at the University of Pittsburgh on "ANDROGEN RECEPTOR NUCLEAR LOCALIZATION IN CASTRATION-RESISTANT PROSTATE CANCER". The research project, which runs from March 1, 2024 to February 28, 2027, aims to investigate the role of androgen receptor localization in prostate cancer that has become resistant to androgen deprivation therapy. As a...
The University of Pittsburgh - Of The Commonwealth System of Higher Education, doing business as The University of Pittsburgh, was awarded a $636,000 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research on a novel combination therapy targeting growth factor receptor cross talk with epitranscriptomic regulation in glioblastoma, a type of brain cancer, with the goal of developing innovative medical...
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $3,333,240 project grant to the Allegheny Singer Research Institute (AHN Research Institute) to conduct research on "Understanding the Effects of Intracavitary Conditioning in Breast Cancer Metastatic to the Pleura or the Peritoneum." The grant period runs from June 1, 2025 to May 31, 2029. As a sophisticated medical research organization with an extensive federal grant portfolio,...